Date,KTTA_Close,KTTA_Volume,Title,Summary,Sentiment,Date Published
2024-09-25 04:00:00,3.8450000286102295,20800,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-24 04:00:00,3.963000059127808,90600,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-23 04:00:00,4.099999904632568,7800,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-20 04:00:00,4.420000076293945,9400,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-19 04:00:00,4.800000190734863,66400,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-18 04:00:00,5.800000190734863,100500,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-17 04:00:00,4.610000133514404,22600,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-16 04:00:00,3.920000076293945,2100,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-13 04:00:00,3.869999885559082,3600,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-12 04:00:00,3.944999933242798,11100,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-11 04:00:00,3.859999895095825,2000,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-10 04:00:00,3.890000104904175,17900,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-09 04:00:00,4.25,16600,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-06 04:00:00,4.190000057220459,6300,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-05 04:00:00,4.28000020980835,37700,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-04 04:00:00,4.440000057220459,36600,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-09-03 04:00:00,4.849999904632568,8600,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-08-30 04:00:00,4.551000118255615,1500,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-08-29 04:00:00,4.710000038146973,2100,"Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Aug. 28, 2024 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp.",0.0,2024-08-28 13:11:01
2024-08-28 04:00:00,4.559999942779541,3400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.0071428571428571435,2024-04-24 11:59:00
2024-08-27 04:00:00,4.610000133514404,400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.014285714285714287,2024-04-24 11:59:00
2024-08-26 04:00:00,4.599999904632568,2800,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.021428571428571432,2024-04-24 11:59:00
2024-08-23 04:00:00,4.650000095367432,76700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.028571428571428574,2024-04-24 11:59:00
2024-08-22 04:00:00,4.702000141143799,21600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.03571428571428571,2024-04-24 11:59:00
2024-08-21 04:00:00,4.78000020980835,2200,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.042857142857142864,2024-04-24 11:59:00
2024-08-20 04:00:00,4.602000236511231,1900,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-19 04:00:00,4.6570000648498535,14500,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-16 04:00:00,4.64900016784668,5200,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-15 04:00:00,4.590000152587891,2600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-14 04:00:00,4.619999885559082,27400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-13 04:00:00,4.849999904632568,1700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-12 04:00:00,4.800000190734863,3900,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-09 04:00:00,4.849999904632568,10000,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-08 04:00:00,4.849999904632568,107000,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-07 04:00:00,4.75,69100,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-06 04:00:00,5.039999961853027,61400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-05 04:00:00,6.25,107000,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-02 04:00:00,5.0,15100,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-08-01 04:00:00,5.010000228881836,20600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-31 04:00:00,5.25,10700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-30 04:00:00,5.130000114440918,3700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-29 04:00:00,5.199999809265137,2100,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-26 04:00:00,5.050000190734863,2800,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-25 04:00:00,4.659999847412109,9900,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-24 04:00:00,5.190000057220459,3300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-23 04:00:00,5.789999961853027,2300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-22 04:00:00,5.800000190734863,4600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-19 04:00:00,5.849999904632568,3800,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-18 04:00:00,5.989999771118164,1200,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-17 04:00:00,6.019999980926514,1300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-16 04:00:00,5.925000190734863,4200,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-15 04:00:00,6.059999942779541,20200,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-12 04:00:00,5.599999904632568,3400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-11 04:00:00,5.25,10100,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-10 04:00:00,5.21999979019165,3200,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-09 04:00:00,5.568999767303467,3100,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-08 04:00:00,5.150000095367432,3700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-05 04:00:00,5.074999809265137,2600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-03 04:00:00,5.179999828338623,900,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-02 04:00:00,5.15500020980835,2500,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-07-01 04:00:00,5.25,800,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-28 04:00:00,5.060999870300293,700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-27 04:00:00,5.260000228881836,1000,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-26 04:00:00,5.264999866485596,1200,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-25 04:00:00,5.300000190734863,4800,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-24 04:00:00,4.96999979019165,2600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-21 04:00:00,4.739999771118164,1600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-20 04:00:00,4.901999950408936,5700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-18 04:00:00,5.139999866485596,2200,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-17 04:00:00,5.110000133514404,7600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-14 04:00:00,5.260000228881836,3600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-13 04:00:00,5.698999881744385,9700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-12 04:00:00,5.776999950408936,30700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-11 04:00:00,5.570000171661377,45500,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-10 04:00:00,5.599999904632568,900,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-07 04:00:00,5.599999904632568,700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-06 04:00:00,5.690000057220459,400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-05 04:00:00,5.690000057220459,900,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-04 04:00:00,5.605000019073486,500,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-06-03 04:00:00,5.710000038146973,7000,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-31 04:00:00,5.460000038146973,700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-30 04:00:00,5.849999904632568,300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-29 04:00:00,5.849999904632568,3100,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-28 04:00:00,6.300000190734863,2300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-24 04:00:00,6.400000095367432,2500,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-23 04:00:00,6.550000190734863,1500,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-22 04:00:00,6.5980000495910645,300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-21 04:00:00,6.604000091552734,700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-20 04:00:00,6.650000095367432,600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-17 04:00:00,6.599999904632568,400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-16 04:00:00,6.5,2600,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-15 04:00:00,6.650000095367432,1400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-14 04:00:00,6.650000095367432,2700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-13 04:00:00,6.949999809265137,1700,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-10 04:00:00,7.679999828338623,300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-09 04:00:00,7.679999828338623,300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-08 04:00:00,7.050000190734863,800,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-07 04:00:00,7.110000133514404,400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-06 04:00:00,7.130000114440918,3200,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-03 04:00:00,6.920000076293945,0,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-02 04:00:00,6.920000076293945,400,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-05-01 04:00:00,6.920000076293945,0,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-04-30 04:00:00,6.920000076293945,300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-04-29 04:00:00,6.920000076293945,1500,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-04-26 04:00:00,7.239999771118164,0,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-04-25 04:00:00,7.239999771118164,300,"Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers","Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.",-0.05,2024-04-24 11:59:00
2024-04-24 04:00:00,6.949999809265137,900,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",-0.0035714285714285904,2024-02-26 08:09:49
2024-04-23 04:00:00,7.090000152587891,700,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.04285714285714283,2024-02-26 08:09:49
2024-04-22 04:00:00,6.760000228881836,2300,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.08928571428571426,2024-02-26 08:09:49
2024-04-19 04:00:00,7.110000133514404,500,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.13571428571428568,2024-02-26 08:09:49
2024-04-18 04:00:00,7.150000095367432,700,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.18214285714285708,2024-02-26 08:09:49
2024-04-17 04:00:00,7.150000095367432,300,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.22857142857142848,2024-02-26 08:09:49
2024-04-16 04:00:00,7.25,700,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-15 04:00:00,7.150000095367432,1600,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-12 04:00:00,7.460000038146973,1800,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-11 04:00:00,7.650000095367432,3600,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-10 04:00:00,8.199999809265137,900,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-09 04:00:00,8.246000289916992,1600,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-08 04:00:00,8.449999809265137,3100,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-05 04:00:00,8.5,2800,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-04 04:00:00,8.75,14300,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-03 04:00:00,7.989999771118164,8800,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-02 04:00:00,7.229000091552734,7700,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-04-01 04:00:00,7.25,0,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-28 04:00:00,7.25,1700,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-27 04:00:00,7.150000095367432,1500,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-26 04:00:00,7.300000190734863,600,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-25 04:00:00,7.13100004196167,800,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-22 04:00:00,6.702000141143799,900,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-21 04:00:00,7.171999931335449,1200,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-20 04:00:00,6.800000190734863,600,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-19 04:00:00,6.820000171661377,800,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-18 04:00:00,7.114999771118164,1100,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-15 04:00:00,6.9730000495910645,900,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-14 04:00:00,7.199999809265137,1200,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-13 04:00:00,7.275000095367432,2500,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-12 04:00:00,7.224999904632568,1000,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-11 04:00:00,7.5,900,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-08 05:00:00,7.289000034332275,2500,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-07 05:00:00,7.199999809265137,1600,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-06 05:00:00,7.24399995803833,4500,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-05 05:00:00,7.139999866485596,4700,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-04 05:00:00,7.670000076293945,2700,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-03-01 05:00:00,8.130000114440918,2000,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-02-29 05:00:00,8.0,4500,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-02-28 05:00:00,7.599999904632568,9600,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-02-27 05:00:00,7.300000190734863,3800,'Star Trek' And 'Captain Marvel' Actor Kenneth Mitchell Dies At 49,"Canadian actor Kenneth Mitchell, known for his roles in the popular series ""Star Trek: Discovery"" and Marvel's ""Captain Marvel,"" has passed away at the age of 49 after a long battle with Amyotrophic lateral sclerosis ( ALS ) .",0.2749999999999999,2024-02-26 08:09:49
2024-02-26 05:00:00,7.400000095367432,2100,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.24897959183673463,2024-01-02 13:35:05
2024-02-23 05:00:00,7.420000076293945,8400,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.2229591836734693,2024-01-02 13:35:05
2024-02-22 05:00:00,7.199999809265137,8800,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.19693877551020403,2024-01-02 13:35:05
2024-02-21 05:00:00,7.5,6700,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.17091836734693872,2024-01-02 13:35:05
2024-02-20 05:00:00,7.78000020980835,2100,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.1448979591836734,2024-01-02 13:35:05
2024-02-16 05:00:00,7.21999979019165,10700,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.11887755102040812,2024-01-02 13:35:05
2024-02-15 05:00:00,7.236999988555908,13700,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-14 05:00:00,6.485000133514404,7700,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-13 05:00:00,6.449999809265137,3300,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-12 05:00:00,5.920000076293945,2200,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-09 05:00:00,6.050000190734863,1900,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-08 05:00:00,5.820000171661377,4500,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-07 05:00:00,6.03000020980835,18600,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-06 05:00:00,5.951000213623047,11900,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-05 05:00:00,6.400000095367432,2000,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-02 05:00:00,6.5,6300,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-02-01 05:00:00,6.599999904632568,2600,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-31 05:00:00,6.550000190734863,11700,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-30 05:00:00,7.289999961853027,8500,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-29 05:00:00,7.039999961853027,800,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-26 05:00:00,7.150000095367432,2000,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-25 05:00:00,6.96999979019165,4400,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-24 05:00:00,7.050000190734863,44900,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-23 05:00:00,7.75,26100,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-22 05:00:00,6.900000095367432,6300,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-19 05:00:00,7.125,2800,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-18 05:00:00,7.0,6600,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-17 05:00:00,7.316999912261963,34500,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-16 05:00:00,7.25,28400,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-12 05:00:00,7.510000228881836,3100,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-11 05:00:00,7.5,6400,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-10 05:00:00,7.579999923706055,65000,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-09 05:00:00,6.940000057220459,28600,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-08 05:00:00,7.3520002365112305,10100,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-05 05:00:00,7.0,94200,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-04 05:00:00,7.541999816894531,10100,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-03 05:00:00,7.599999904632568,19600,"Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ",-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 - -- Initial readout expected as early as Q3 2024 -,0.0928571428571428,2024-01-02 13:35:05
2024-01-02 05:00:00,8.050000190734863,113400,"Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023","Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.",0.06530612244897956,2023-12-28 22:00:00
2023-12-29 05:00:00,7.400000095367432,13355,"Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023","Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.",0.03775510204081629,2023-12-28 22:00:00
2023-12-28 05:00:00,7.800000190734863,14875,Pasithea Therapeutics Announces Results from 2023 Annual Meeting,Disclosure related to the annual meeting of Pasithea Therapeutics ...,0.024489795918367314,2023-12-19 22:19:00
2023-12-27 05:00:00,8.199999809265137,7945,Pasithea Therapeutics Announces Results from 2023 Annual Meeting,Disclosure related to the annual meeting of Pasithea Therapeutics ...,0.011224489795918344,2023-12-19 22:19:00
2023-12-26 05:00:00,8.65999984741211,53695,Pasithea Therapeutics Announces Results from 2023 Annual Meeting,Disclosure related to the annual meeting of Pasithea Therapeutics ...,-0.002040816326530629,2023-12-19 22:19:00
2023-12-22 05:00:00,7.960000038146973,28030,Pasithea Therapeutics Announces Results from 2023 Annual Meeting,Disclosure related to the annual meeting of Pasithea Therapeutics ...,-0.0153061224489796,2023-12-19 22:19:00
2023-12-21 05:00:00,5.71999979019165,8990,Pasithea Therapeutics Announces Results from 2023 Annual Meeting,Disclosure related to the annual meeting of Pasithea Therapeutics ...,-0.028571428571428574,2023-12-19 22:19:00
2023-12-20 05:00:00,5.599999904632568,22970,Pasithea Therapeutics Announces Results from 2023 Annual Meeting,Disclosure related to the annual meeting of Pasithea Therapeutics ...,-0.014285714285714287,2023-12-19 22:19:00
2023-12-19 05:00:00,6.480000019073486,11220,"Nasdaq Edges Higher; Macy's Shares Jump - Cigna Group  ( NYSE:CI ) , Cogent Biosciences  ( NASDAQ:COGT ) ","U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11. Industrials shares rose by 0.8% on Monday.",0.0732142857142857,2023-12-11 19:26:20
2023-12-18 05:00:00,6.900000095367432,10725,"Nasdaq Edges Higher; Macy's Shares Jump - Cigna Group  ( NYSE:CI ) , Cogent Biosciences  ( NASDAQ:COGT ) ","U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11. Industrials shares rose by 0.8% on Monday.",0.1464285714285714,2023-12-11 19:26:20
2023-12-15 05:00:00,7.0,19240,"Nasdaq Edges Higher; Macy's Shares Jump - Cigna Group  ( NYSE:CI ) , Cogent Biosciences  ( NASDAQ:COGT ) ","U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11. Industrials shares rose by 0.8% on Monday.",0.2196428571428571,2023-12-11 19:26:20
2023-12-14 05:00:00,7.420000076293945,29690,"Nasdaq Edges Higher; Macy's Shares Jump - Cigna Group  ( NYSE:CI ) , Cogent Biosciences  ( NASDAQ:COGT ) ","U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11. Industrials shares rose by 0.8% on Monday.",0.2928571428571428,2023-12-11 19:26:20
2023-12-13 05:00:00,9.140000343322754,48845,"Nasdaq Edges Higher; Macy's Shares Jump - Cigna Group  ( NYSE:CI ) , Cogent Biosciences  ( NASDAQ:COGT ) ","U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11. Industrials shares rose by 0.8% on Monday.",0.36607142857142855,2023-12-11 19:26:20
2023-12-12 05:00:00,8.880000114440918,168940,"Nasdaq Edges Higher; Macy's Shares Jump - Cigna Group  ( NYSE:CI ) , Cogent Biosciences  ( NASDAQ:COGT ) ","U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11. Industrials shares rose by 0.8% on Monday.",0.4392857142857142,2023-12-11 19:26:20
2023-12-11 05:00:00,8.84000015258789,4973815,"Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Aditxt  ( NASDAQ:ADTX ) , Ampio Pharmaceuticals  ( AMEX:AMPE ) ","Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 ...",0.4392857142857142,2023-11-30 13:01:37
2023-12-08 05:00:00,6.0,415,"Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Aditxt  ( NASDAQ:ADTX ) , Ampio Pharmaceuticals  ( AMEX:AMPE ) ","Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 ...",0.36607142857142855,2023-11-30 13:01:37
2023-12-07 05:00:00,6.579999923706055,1025,"Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Aditxt  ( NASDAQ:ADTX ) , Ampio Pharmaceuticals  ( AMEX:AMPE ) ","Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 ...",0.2928571428571428,2023-11-30 13:01:37
2023-12-06 05:00:00,5.880000114440918,1565,"Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Aditxt  ( NASDAQ:ADTX ) , Ampio Pharmaceuticals  ( AMEX:AMPE ) ","Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 ...",0.2196428571428571,2023-11-30 13:01:37
2023-12-05 05:00:00,5.900000095367432,1625,"Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Aditxt  ( NASDAQ:ADTX ) , Ampio Pharmaceuticals  ( AMEX:AMPE ) ","Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 ...",0.1464285714285714,2023-11-30 13:01:37
2023-12-04 05:00:00,6.199999809265137,825,"Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Aditxt  ( NASDAQ:ADTX ) , Ampio Pharmaceuticals  ( AMEX:AMPE ) ","Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 ...",0.0732142857142857,2023-11-30 13:01:37
2023-12-01 05:00:00,6.380000114440918,1620,"Why Salesforce Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Aditxt  ( NASDAQ:ADTX ) , Ampio Pharmaceuticals  ( AMEX:AMPE ) ","Shares of Salesforce, Inc. CRM shares surged in pre-market trading after the company reported third-quarter financial results and issued FY24 guidance above estimates. Salesforce said third-quarter revenue increased 11% year-over-year to $8.72 billion, versus the consensus estimate of $8.72 ...",0.0,2023-11-30 13:01:37
2023-11-30 05:00:00,6.519999980926514,5205,"Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders - Pasithea Therapeutics  ( NASDAQ:KTTA ) , Pasithea Therapeutics  ( NASDAQ:KTTAW ) ","SOUTH SAN FRANCISCO, Calif. and MIAMI, Nov. 29, 2023 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. ( ""Pasithea"" or the ""Company"" ) KTTA, today announced that its annual meeting of stockholders held on November 29, 2023 ( the ""Annual Meeting"" ) was convened and then adjourned, without ...",0.0,2023-11-29 21:27:00
2023-11-29 05:00:00,7.079999923706055,37175,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-28 05:00:00,6.639999866485596,1210,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-27 05:00:00,6.920000076293945,1435,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-24 05:00:00,6.179999828338623,975,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-22 05:00:00,6.0,1015,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-21 05:00:00,6.440000057220459,115,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-20 05:00:00,6.420000076293945,595,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-17 05:00:00,6.199999809265137,1330,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-16 05:00:00,6.0,2885,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-15 05:00:00,6.599999904632568,905,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-14 05:00:00,6.519999980926514,1485,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-13 05:00:00,6.199999809265137,1225,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-10 05:00:00,7.420000076293945,860,"Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS","Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS ...",0.0,2023-11-09 12:59:00
2023-11-09 05:00:00,7.5,750,,,0.0,
2023-11-08 05:00:00,7.5,200,,,0.0,
2023-11-07 05:00:00,7.139999866485596,1150,,,0.0,
2023-11-06 05:00:00,7.380000114440918,440,,,0.0,
2023-11-03 04:00:00,7.199999809265137,1930,,,0.0,
2023-11-02 04:00:00,6.400000095367432,1005,,,0.0,
2023-11-01 04:00:00,7.0,165,,,0.0,
2023-10-31 04:00:00,7.0,670,,,0.0,
2023-10-30 04:00:00,7.119999885559082,1115,,,0.0,
2023-10-27 04:00:00,7.039999961853027,985,,,0.0,
2023-10-26 04:00:00,7.239999771118164,1415,,,0.0,
2023-10-25 04:00:00,7.960000038146973,8605,,,0.0,
2023-10-24 04:00:00,8.199999809265137,580,,,0.0,
2023-10-23 04:00:00,8.720000267028809,245,,,0.0,
2023-10-20 04:00:00,9.399999618530272,1085,,,0.0,
2023-10-19 04:00:00,9.399999618530272,1285,,,0.0,
2023-10-18 04:00:00,8.399999618530273,155,,,0.0,
2023-10-17 04:00:00,9.020000457763672,1830,,,0.0,
2023-10-16 04:00:00,8.5,575,,,0.0,
2023-10-13 04:00:00,8.800000190734863,1530,,,0.0,
2023-10-12 04:00:00,8.65999984741211,1565,,,0.0,
2023-10-11 04:00:00,8.239999771118164,695,,,0.0,
2023-10-10 04:00:00,8.479999542236328,520,,,0.0,
2023-10-09 04:00:00,8.0,150,,,0.0,
2023-10-06 04:00:00,8.0600004196167,490,,,0.0,
2023-10-05 04:00:00,8.479999542236328,1700,,,0.0,
2023-10-04 04:00:00,8.0600004196167,2240,,,0.0,
2023-10-03 04:00:00,8.800000190734863,2375,,,0.0,
2023-10-02 04:00:00,9.5,665,,,0.0,
